

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

J. A. Loune  
Signature of Authorized Individual\*

3/20/2020  
Date

Jon Loune  
Printed Name of Authorized Individual

3/20/2020  
Date

\*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

**SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)**

Case No.	Debtor Entity Name:	Net Receipts <sup>2</sup>	Net Disbursements <sup>1</sup>
19-23648	PURDUE PHARMA INC.	407,909	\$ 502,037
19-23649	PURDUE PHARMA L.P.	127,048,193	\$ 65,251,761
19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	\$ -
19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	\$ 159,648
19-23652	PURDUE PHARMACEUTICALS L.P.	-	\$ 2,969,846
19-23653	IMBRIUM THERAPEUTICS L.P.	-	\$ 1,018,068
19-23654	ADLON THERAPEUTICS L.P.	-	\$ 4,077,581
19-23655	GREENFIELD BIO VENTURES L.P.	-	\$ 146,250
19-23656	SEVEN SEAS HILL CORP.	-	\$ -
19-23657	OPHIR GREEN CORP.	-	\$ -
19-23658	PURDUE PHARMA OF PUERTO RICO	-	\$ 524
19-23659	AVRIO HEALTH L.P.	-	\$ 4,125,111
19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	\$ 8,595
19-23661	PURDUE NEUROSCIENCE COMPANY	-	\$ -
19-23662	NAYATT COVE LIFESCIENCE INC.	500,386	\$ 291,250
19-23663	BUTTON LAND L.P.	-	\$ -
19-23664	PAUL LAND INC.	-	\$ -
19-23665	QUIDNICK LAND L.P.	-	\$ -
19-23666	RHODES ASSOCIATES L.P.	-	\$ -
19-23667	RHODES PHARMACEUTICALS L.P.	21,546,107	\$ 9,615,756
19-23668	RHODES TECHNOLOGIES	852,745	\$ 5,047,418
19-23669	UDF LP	-	\$ -
19-23670	SVC PHARMA LP	-	\$ 125,088
19-23671	SVC PHARMA INC.	-	\$ -
<b>Totals:</b>		<b>\$ 150,355,340</b>	<b>\$ 93,338,932</b>

**Footnotes**

- 1) The Net Disbursements exclude intercompany transactions among Debtors
- 2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 29, 2020

**BANK ACCOUNT BALANCES (\$)**

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	750,000
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,840,392
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,012,697
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	3,504,416
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,662,094
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Account	201,226,539
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Account	100,289,459
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx8720	Account	100,157,887
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxxx8266	Money Market Fund	53,752,713
Purdue Pharma L.P.	Goldman Sachs #506	xxxxx0462	Money Market Fund	677,716,556
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	19,400,827
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	203,127
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx6017	Trust	15,133,000
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,248,547
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	59,037,620
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,014,874
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	125,319,567
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,367,991
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx4018	Trust	25,078,071
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	367,506
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxxx5300	Trust	125,637
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 29, 2020

**BANK ACCOUNT BALANCES (\$)**

<b>Debtor</b>	<b>Bank</b>	<b>Account Number</b>	<b>Description</b>	<b>Balance as of Month End</b>
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-
Rhodes Technologies	JP Morgan Chase	xxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
<b>Total</b>				<b>1,437,560,184</b>

In re: **PURDUE PHARMA L.P., et al.,  
Debtors**

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

**CONSOLIDATED STATEMENT OF OPERATIONS (\$M)** <sup>1,2</sup>  
**Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.**

	<b>Current Month</b>	<b>2020 Year to Date</b>	<b>2019 Cumulative Filing to Date</b> <sup>3</sup>
Net Sales	67	\$157	\$468
Cost of Goods Sold	(9)	(30)	(30)
Royalty Expense	-	(3)	(3)
Shipping and Warehousing	-	(1)	(1)
Cost of Goods Sold	(9)	(34)	(134)
Gross Profit	58	123	333
Sales and Promotion	(7)	(18)	(56)
Research and Development	(2)	(11)	(45)
General and Administrative	(7)	(16)	(56)
Legal Fees - Ordinary Course	-	(1)	(4)
Medical Affairs	(3)	(6)	(17)
Milestones & Alliances	(3)	(3)	(4)
Health Care Reform Fee	(2)	(3)	(7)
Other US	(1)	(1)	(2)
Incentive Bonus	(3)	(6)	(22)
Insurance Income	-	-	-
Settlement Expense	-	-	-
Total Operating Expenses	(28)	(65)	(213)
Operating Profit	29	57	120
Legal Fees - Non-Recurring	(26)	(46)	(143)
Other	-	-	(7)
Total Non-Operating Expenses	(26)	(46)	(150)
Profit	3	11.1	(\$30)

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000) <sup>1,2</sup>

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Management Fee Income	29	\$58	\$173
General and Administrative Expenses	(1)	(15)	(44)
Operating Income	28	43	129
		-	
Other income:	-	-	-
Income from Unconsolidated Associated Companies	20	79	(57)
Interest income - associated companies	-	-	-
Total Other Income	20	79	(57)
		-	
Pre-Tax Income	48	122	72
		-	
Income Tax Provision	(13)	(33)	(65)
		-	
Net Income	35	89.0	\$6
		-	

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 29, 2020

CONSOLIDATED BALANCE SHEET (\$M) <sup>1,2</sup>	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
<b>ASSETS</b>	
<b>CURRENT ASSETS</b>	
Cash & Cash Equivalents	\$1,152
Available For Sale Investments	1
Accounts Receivable, Net	82
Due From Associated Companies	8
Other Receivables	3
Inventories, Net	91
Contribution Receivable	-
Prepaid Expenses & Other Current Assets	83
Restricted Cash	13
<b>TOTAL CURRENT ASSETS</b>	<b>1,433</b>
Property and Equipment, net	139
Investments at Cost	28
Investments in Associated Companies	-
Restricted Cash - Long-Term	272
Intangible Assets, Net	101
Other Assets	17
<b>TOTAL ASSETS</b>	<b>\$1,990</b>
<b>LIABILITIES AND EQUITY</b>	
<b>CURRENT LIABILITIES</b>	
Accounts Payable	\$62
Accrued Expenses	401
Due to Associated Companies	2
<b>TOTAL CURRENT LIABILITIES</b>	<b>465</b>
Other Liabilities	106
Due to Associated Companies	11
Liabilities Subject to Compromise <sup>3</sup>	3,017
<b>TOTAL LIABILITIES</b>	<b>3,599</b>
<b>EQUITY</b>	
Retained Earnings & Partners' Capital	(1,564)
Accumulated Other Comprehensive Loss	(45)
<b>TOTAL EQUITY</b>	<b>(1,609)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$1,990</b>

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 29, 2020

**PURDUE PHARMA, INC. BALANCE SHEET (\$000) <sup>1,2</sup>**

	Book Value
<b>Assets</b>	
Currents assets:	
Cash and cash equivalents	\$367
Prepaid expenses	98
Due from Associated Companies	948
<b>Total current assets</b>	<b>1,413</b>
Investments	8,897
Deferred income taxes	147
<b>Total assets</b>	<b>\$10,457</b>
<b>Liabilities and equity</b>	
Current liabilities:	
Accounts payable	\$711
Due to Associated Companies	175
Accrued Expenses	178
<b>Total liabilities</b>	<b>1,064</b>
Common stock	1
Additional paid-in capital	499
Retained earnings	8,958
Accumulated other comprehensive loss	(65)
<b>Total equity</b>	<b>9,393</b>
<b>Total liabilities and equity</b>	<b>\$10,457</b>

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

**SCHEDULE OF POST PETITION TAXES**

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



\_\_\_\_\_  
Signature

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Compensation</b>		
Chomiak, Caroline	25,632	156,168
Kesselman, Marc L <sup>2</sup>	168,219	890,517
Landau, Craig J	236,270	1,262,465
Lowne, Jonathan R	83,566	440,479
Lundie, David R	66,665	360,549
Mancinelli II, Vincent F	40,935	221,502
Mazzi, Christian	-	439,030
Medeiros, Paul	55,950	285,662
Shamblen, Randy	40,066	216,775
Strassburger, Philip C	78,249	399,238
<b>Total Compensation</b>	<b>795,551</b>	<b>4,672,387</b>
<b>Director Fees</b>		
Boer, F Peter	-	350,000
Buckfire, Kenneth A	-	350,000
Cola, Michael	-	350,000
Collins, Michael J	-	25,000
Dubel, John	-	350,000
Miller, Robert S	208,333	833,333
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	-	350,000
<b>Total Director Fees</b>	<b>208,333</b>	<b>2,633,333</b>
<b>T&amp;E Reimbursements</b>		
Boer, F Peter	2,744	10,907
Buckfire, Kenneth A	-	1,179
Chomiak, Caroline	2,568	31,848
Cola, Michael	-	764
Debone, Louis	-	1,245
Dubel, John	767	4,513
Kesselman, Marc L	5,854	43,794
Landau, Craig J	10,460	52,925
Lowne, Jonathan R	276	1,065
Lundie, David R	6,715	26,389
Mancinelli II, Vincent F	2,160	40,690
Mazzi, Christian	-	3,734
Medeiros, Paul	7,379	28,194
Miller, Robert S	1,756	6,170
Pickett, Cecil	-	1,298
Shamblen, Randy	494	9,679
Strassburger, Philip C	744	12,027
<b>Total T&amp;E Reimbursements</b>	<b>41,918</b>	<b>276,421</b>
<b>Housing Payments</b>		
Kesselman, Marc L	4,673	27,811
<b>Total Housing Payments</b>	<b>4,673</b>	<b>27,811</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b><i>Indemnification Payments</i></b>		
Butcher, James A	-	527
Friedman, Michael	-	25,424
Landau, Craig J	257,886	570,381
Motahari, Saeed	-	14,320
Stewart, John	50,656	69,569
Timney, Mark	727,210	728,718
Purdue Pharma Inc Independent Directors <sup>3</sup>	517,468	517,468
<b>Total Indemnification Payments</b>	<b>1,553,220</b>	<b>1,926,408</b>
<b><i>Payments to Independent Associated Companies</i></b>		
Mundibiopharma Ltd	-	55,332
Mundipharma IT Services LTD	-	229,088
Mundipharma Laboratories GmbH	-	271,128
Mundipharma Research LTD	63,532	63,532
Mundipharma Singapore Holdings Pte Ltd	60,675	60,675
One Stamford Realty L.P.	737,361	3,959,703
Purdue Pharma Canada	122,060	1,479,161
TXP Services Inc. <sup>4</sup>	1,060,398	3,594,704
<b>Total Payments to Independent Associated Companies</b>	<b>2,044,026</b>	<b>9,713,322</b>
<b>Total Payments to Insiders</b>	<b>4,647,722</b>	<b>19,249,681</b>

**Footnotes**

1) Represents payments made since the Commencement Date.

2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.

3) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snyderman, Ralph.

4) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

**SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1,2</sup>
<b><i>Estate Professionals</i></b>		
Davis Polk & Wardwell LLP	3,284,711	15,381,620
AlixPartners, LLP	1,329,209	2,026,068
PJT Partners LP	-	-
Prime Clerk LLC	23,486,565	25,408,142
<b>Total Estate Professionals</b>	<b>28,100,485</b>	<b>42,815,829</b>
<b><i>Creditor Committee Professionals</i></b>		
Akin Gump Strauss Hauer & Feld LLP	3,971,390	3,971,390
Bayard, P.A.	260,756	260,756
Jefferies LLC	-	-
Province, Inc.	990,189	2,065,668
Kurtzman Carson Consultants LLC	-	-
<b>Total Creditor Committee Professionals</b>	<b>5,222,335</b>	<b>6,297,814</b>
<b><i>Ad Hoc Committee Professionals</i></b>		
Kramer Levin Naftalis & Frankel LLP	555,225	1,464,965
Brown Rudnick LLP	180,189	667,091
Gilbert LLP	123,038	478,517
Otterbourg PC	106,897	382,637
FTI Consulting, Inc	662,959	1,286,673
Compass Lexecon	-	-
Coulter & Justice	-	-
<b>Total Ad Hoc Committee Professionals</b>	<b>1,628,308</b>	<b>4,279,883</b>
<b><i>Special Counsel to the Debtors</i></b>		
Arnold Porter & Kaye Scholer	-	-
Dechert LLP	-	-
Jones Day	-	-
King & Spalding LLP	-	2,142,346
Skadden, Arps, Slate, Meagher & Flom LLP	-	1,427,890
Wilmer Cutler Pickering Hale and Door LLP	-	-
<b>Total Special Counsel Professionals</b>	<b>-</b>	<b>3,570,236</b>
<b>The Law Offices of Kenneth Feinberg (Mediator)</b>	<b>-</b>	<b>-</b>
<b>Phillips ADR (Mediator)</b>	<b>-</b>	<b>-</b>
<b>Ernst &amp; Young (Canada), Court Appointed Information Officer</b>	<b>-</b>	<b>284,159</b>
<b>Total Retained Restructuring Professional Fees</b>	<b>34,951,128</b>	<b>57,247,921</b>

**Footnotes**

1) Represents payments made since the Commencement Date

2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2020 to February 29, 2020

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?	X		Payments have been made pursuant to the First Day Order authorizing the Debtors to pay certain prepetition taxes
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	